PureTech Reports Results from Phase 2 Study of LYT-100-COV in Post-Acute “Long” COVID with Respiratory Complications
No treatment effect observed in this patient population; substantial improvement in 6-minute walk test seen in both placebo and active groups Study adds to growing body of data supporting strong safety and tolerability profile of LYT-100 (deupirfenidone) Company will drive LYT-100 forward in other indications, with a focus on IPF where human clinical efficacy has … [Read more…]